비스테로이드성 항염증약(NSAIDs) 시장 규모, 점유율, 성장 분석 : 약제 유형별, 투여 경로별, 용도별, 유통 채널별, 최종사용자별, 제형별, 지역별 - 산업 예측(2026-2033년)

Global Non-Steroidal Anti-Inflammatory Drugs Market size was valued at USD 24.8 Billion in 2024 and is poised to grow from USD 26.21 Billion in 2025 to USD 40.84 Billion by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033).

The global non-steroidal anti-inflammatory drugs (NSAIDs) market is significantly driven by the continuous demand for effective pain and inflammation relief, fueled by an aging population and a rise in chronic conditions like osteoarthritis and rheumatoid arthritis. This market includes a mix of over-the-counter analgesics and prescription drugs, with the evolution from historical salicylates to modern COX-2 innovations enhancing perceptions of safety. Key factors propelling growth include increased genericization and innovative formulations, enabling manufacturers to create differentiated products such as topical gels and extended-release tablets. Additionally, artificial intelligence is optimizing NSAID development by streamlining target identification and improving clinical planning, thus reducing development bottlenecks and enhancing manufacturing efficiency. Companies are focusing on emerging markets and chronic care partnerships, creating scalable growth opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Steroidal Anti-Inflammatory Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Steroidal Anti-Inflammatory Drugs Market Segments Analysis

Global non-steroidal anti-inflammatory drugs market is segmented by drug type, route of administration, application, distribution channel, end user, dosage form and region. Based on drug type, the market is segmented into Ibuprofen, Naproxen, Aspirin, Diclofenac, Celecoxib, Ketorolac and Others. Based on route of administration, the market is segmented into Oral, Topical, Injectable and Others. Based on application, the market is segmented into Pain Management, Arthritis Treatment, Fever Management, Postoperative Pain, Musculoskeletal Disorders and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on end user, the market is segmented into Hospitals, Clinics, Home Care Settings, Sports Medicine Centers and Others. Based on dosage form, the market is segmented into Tablets & Capsules, Creams & Gels, Injections, Suspensions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Steroidal Anti-Inflammatory Drugs Market

The Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market is significantly driven by the persistent demand for effective pain relief solutions applicable to various acute and chronic conditions. Healthcare professionals often favor NSAIDs due to their rapid efficacy and well-documented safety profiles, which leads to increased prescription rates and patient acceptance. In response, pharmaceutical companies focus on ensuring strong production capabilities and reliable supply chains while enhancing awareness and familiarity among healthcare providers regarding these drugs. This combination supports the ongoing reliance on NSAIDs in both outpatient and inpatient settings, reinforcing their essential role in pain management strategies globally.

Restraints in the Global Non-Steroidal Anti-Inflammatory Drugs Market

Ongoing safety concerns regarding the gastrointestinal, cardiovascular, and renal side effects linked to the use of non-steroidal anti-inflammatory drugs prompt healthcare professionals to approach therapy selection with increased caution, particularly for at-risk populations. This heightened awareness of potential risks has led to stricter regulatory advisories and more conservative treatment guidelines that discourage the indiscriminate prescribing of these medications. Consequently, there is a shift towards alternative analgesics and non-pharmacological treatments, which restricts market growth. Additionally, this cautious approach impacts product positioning, compelling manufacturers to prioritize safety communication and risk mitigation strategies over aggressive expansion tactics in their market endeavors.

Market Trends of the Global Non-Steroidal Anti-Inflammatory Drugs Market

The Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market is witnessing a significant shift towards integrated digital care models, enhancing treatment accessibility and personalization. The convergence of digital platforms with clinical workflows facilitates telemedicine consultations and real-time symptom tracking, enabling healthcare providers to customize NSAID therapies effectively. This trend is further propelled by a focus on value-based healthcare, which prioritizes patient outcomes and experience, encouraging innovative formulations that support remote patient management. Collaborative efforts among pharmaceutical companies, health IT developers, and healthcare providers are fostering an ecosystem that allows NSAIDs to be differentiated through connected patient care solutions, ultimately enhancing market growth and competitiveness.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Non-steroidal Anti-inflammatory Drugs Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Ibuprofen
• Naproxen
• Aspirin
• Diclofenac
• Celecoxib
• Ketorolac
• Others

Global Non-steroidal Anti-inflammatory Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Topical
• Injectable
• Others

Global Non-steroidal Anti-inflammatory Drugs Market Size by Application & CAGR (2026-2033)

• Market Overview
• Pain Management
• Arthritis Treatment
• Fever Management
• Postoperative Pain
• Musculoskeletal Disorders
• Others

Global Non-steroidal Anti-inflammatory Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Non-steroidal Anti-inflammatory Drugs Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Home Care Settings
• Sports Medicine Centers
• Others

Global Non-steroidal Anti-inflammatory Drugs Market Size by Dosage Form & CAGR (2026-2033)

• Market Overview
• Tablets & Capsules
• Creams & Gels
• Injections
• Suspensions
• Others

Global Non-steroidal Anti-inflammatory Drugs Market Size & CAGR (2026-2033)

• North America (Drug Type, Route of Administration, Application, Distribution Channel, End User, Dosage Form)
  • US
  • Canada
• Europe (Drug Type, Route of Administration, Application, Distribution Channel, End User, Dosage Form)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Route of Administration, Application, Distribution Channel, End User, Dosage Form)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Route of Administration, Application, Distribution Channel, End User, Dosage Form)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Route of Administration, Application, Distribution Channel, End User, Dosage Form)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo International plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations